Filtros de búsqueda

Lista de obras de John C Byrd

17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition

artículo científico publicado en 2010

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

A New Role for Lyn in the CLL Microenvironment

artículo científico publicado en 2016

A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders ⬇️

artículo científico publicado el 14 de agosto de 2012

A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells

scientific article published on 10 March 2016

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

scholarly article

A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia

artículo científico publicado en 2014

A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors

artículo científico publicado en 2009

A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors ⬇️

artículo científico publicado el 12 de octubre de 2010

A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents

artículo científico publicado en 2008

A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism

artículo científico publicado en 2004

A novel liposomal formulation of FTY720 (Fingolimod) for promising enhanced targeted delivery ⬇️

artículo científico publicado el 20 de agosto de 2013

A novel liposomal formulation of flavopiridol

artículo científico publicado en 2008

A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.

artículo científico publicado en 2018

A novel ultrasensitive hybridization-based ELISA method for 2-methoxyphosphorothiolate microRNAs and its in vitro and in vivo application

artículo científico publicado en 2010

A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol

artículo científico publicado en 2013

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

artículo científico publicado en 2004

A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy

artículo científico publicado en 2016

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

artículo científico publicado en 2014

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

artículo científico publicado en 2014

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

artículo científico publicado en 2017

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma

artículo científico publicado en 2014

A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701 ⬇️

artículo científico publicado el 6 de agosto de 2013

A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia

artículo científico publicado en 2008

A phase I trial of flavopiridol in relapsed multiple myeloma

artículo científico publicado en 2013

A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

artículo científico publicado en 2016

A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia

artículo científico publicado en 2009

A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma

artículo científico publicado en 2006

A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia

artículo científico publicado en 2016

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relap

artículo científico publicado en 2014

AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia ⬇️

artículo científico publicado el 14 de octubre de 2011

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

artículo científico publicado en 2015

Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform

artículo científico publicado en 2006

Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor

artículo científico publicado en 2017

Acute myeloid leukemia clinical practice guidelines in oncology

artículo científico publicado en 2006

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

artículo científico publicado en 2004

Adult Burkitt leukemia and lymphoma

artículo científico publicado en 2004

Advances in the therapy of chronic lymphocytic leukemia

artículo científico publicado en 2003

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

artículo científico publicado en 2004

Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function

artículo científico publicado en 2015

Antibody therapy for chronic lymphocytic leukemia: a promising new modality

artículo científico publicado en 2004

Antibody therapy in chronic lymphocytic leukemia.

artículo científico publicado en 2003

Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma ⬇️

artículo científico publicado el 2 de mayo de 2011

Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance

artículo científico publicado en 2003

Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro

artículo científico publicado en 2010

Assaying pharmacodynamic endpoints with targeted therapy: flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia

artículo científico publicado en 2010

Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia

artículo científico publicado en 2014

Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol ⬇️

artículo científico publicado el 1 de marzo de 2013

BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation

artículo científico publicado en 2015

BRD4 profiling identifies critical Chronic Lymphocytic Leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor

artículo científico publicado en 2018

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

artículo científico publicado en 2017

Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia

artículo científico publicado en 2007

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 ⬇️

artículo científico publicado el 21 de marzo de 2011

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

artículo científico publicado en 2013

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

artículo científico publicado en 2010

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody

artículo científico publicado en 2009

CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia

artículo científico publicado en 2001

CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia

artículo científico publicado en 2015

Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia

artículo científico publicado en 2005

Changing the way we think about chronic lymphocytic leukemia

artículo científico publicado en 2005

Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling

artículo científico publicado en 2015

Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease

artículo científico publicado en 2013

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials ⬇️

artículo científico publicado en 2017

Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method

artículo científico publicado en 2006

Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method

artículo científico publicado en 2007

Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia

artículo científico publicado en 2006

Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib

artículo científico publicado en 2018

Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712

artículo científico publicado en 2011

Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines

artículo científico publicado en 2005

Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor-targeted liposomes

artículo científico publicado en 2007

Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance).

artículo científico publicado en 2016

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug

artículo científico publicado en 2008

Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches

artículo científico publicado en 2012

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015

artículo científico publicado en 2015

Chronic lymphocytic leukemia: state of the art and beyond

artículo científico publicado en 2014

Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer

artículo científico publicado en 2017

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia ⬇️

artículo científico publicado el 7 de mayo de 2012

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

artículo científico publicado en 2010

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

artículo científico publicado en 2008

Clinical roundtable monograph: unmet needs in the treatment of chronic lymphocytic leukemia: integrating a targeted approach

artículo científico publicado en 2014

Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma ⬇️

artículo científico publicado el 12 de enero de 2011

Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma

artículo científico publicado en 2009

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

artículo científico publicado en 2007

Community-based phase II trial of PCR for CLL/SLL patients

artículo científico publicado en 2007

Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties

artículo científico publicado en 2013

Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma

artículo científico publicado en 2014

Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia

artículo científico publicado en 2012

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

artículo científico publicado en 2007

Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria

artículo científico publicado en 2007

Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation

artículo científico publicado en 2017

CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia

artículo científico publicado en 2006

CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathway

artículo científico publicado en 2015

Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia

artículo científico publicado en 2016

Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia ⬇️

artículo científico publicado el 15 de julio de 2013

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US i

artículo científico publicado en 2015

DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia

artículo científico publicado en 2016

Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model

artículo científico publicado en 2016

Decitabine in chronic leukemias

artículo científico publicado en 2005

Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing

artículo científico publicado en 2009

Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein

artículo científico publicado en 2003

Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons

artículo científico publicado en 2013

Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma

artículo científico publicado en 2008

Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule

artículo científico publicado en 2008

Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease

artículo científico publicado en 2009

Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia

artículo científico publicado en 2010

Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry

artículo científico publicado en 2004

Differential role for cyclic AMP response element binding protein-1 in multiple stages of B cell development, differentiation, and survival

artículo científico publicado en 2006

Diffuse Large B-Cell Lymphoma Version 1.2016

scientific article published on 01 February 2016

Dose escalation of lenalidomide in relapsed or refractory acute leukemias

artículo científico publicado en 2010

Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia

artículo científico publicado en 2007

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas ⬇️

artículo científico publicado el 23 de enero de 2012

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib

artículo científico publicado en 2017

Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia

artículo científico publicado en 2005

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol ⬇️

artículo científico publicado el 27 de junio de 2012

Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma

artículo científico publicado en 2012

Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia

artículo científico publicado en 2009

Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.

artículo científico publicado en 2005

Emerging drug profile: cyclin-dependent kinase inhibitors

artículo científico publicado en 2013

Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate ⬇️

artículo científico publicado el 1 de febrero de 2011

Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.

artículo científico publicado en 2014

Epigenetic alterations in a murine model for chronic lymphocytic leukemia

artículo científico publicado en 2009

Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia

artículo científico publicado en 2009

Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets

artículo científico publicado en 2004

Epigenetic silencing of miR-708 enhances NF-κB signaling in chronic lymphocytic leukemia

artículo científico publicado en 2015

Epigenetics in chronic lymphocytic leukemia

artículo científico publicado en 2006

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score

artículo científico publicado en 2013

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

artículo científico publicado en 2015

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials

artículo científico publicado en 2018

Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia

artículo científico publicado en 2013

Expression and prognostic impact of lncRNAs in acute myeloid leukemia

artículo científico publicado en 2014

Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia

artículo científico publicado en 2007

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

artículo científico publicado en 2017

Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia

artículo científico publicado en 2012

Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients

artículo científico publicado en 2015

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

artículo científico publicado en 2004

FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma

artículo científico publicado en 2007

FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death ⬇️

artículo científico publicado el 31 de octubre de 2011

FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling

artículo científico publicado en 2008

FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma

artículo científico publicado en 2010

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

artículo científico publicado en 2007

FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways

artículo científico publicado en 2006

Fcγ receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies

scientific article published on 31 July 2013

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia ⬇️

artículo científico publicado el 16 de octubre de 2003

Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia

artículo científico publicado en 2015

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.

artículo científico publicado en 2018

Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity

artículo científico publicado en 2005

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

artículo científico publicado en 2006

Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma

artículo científico publicado en 2013

Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium

artículo científico publicado en 2008

Flavopiridol in chronic lymphocytic leukemia: a concise review

artículo científico publicado en 2009

Flavopiridol in the treatment of chronic lymphocytic leukemia

artículo científico publicado en 2007

Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition

artículo científico publicado en 2010

Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach

artículo científico publicado en 2012

Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders

artículo científico publicado en 2009

Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.

artículo científico publicado en 2009

Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).

artículo científico publicado en 2018

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

artículo científico publicado en 2002

Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines ⬇️

artículo científico publicado el 19 de junio de 2013

Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia

artículo científico publicado en 2019

Genetic heterogeneity of diffuse large B-cell lymphoma

artículo científico publicado en 2013

Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma

scientific article published on 22 January 2014

Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA

artículo científico publicado en 2018

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

artículo científico publicado en 2012

Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia

artículo científico publicado en 2016

Germline allele-specific expression of DAPK1 in chronic lymphocytic leukemia

artículo científico publicado en 2013

Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia

artículo científico publicado en 2005

Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies

artículo científico publicado en 2013

Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity

artículo científico

Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia

artículo científico publicado en 2018

HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide

artículo científico publicado en 2015

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

artículo científico publicado en 2017

Have we forgotten the purpose of phase III studies?

artículo científico publicado en 2007

Hearing Loss due to Infiltration of the Tympanic Membrane by Chronic Lymphocytic Leukemia ⬇️

artículo científico publicado el 7 de noviembre de 2012

High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation

artículo científico publicado en 2006

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

artículo científico publicado en 2008

High‐sensitivity TFA‐free LC‐MS for profiling histones ⬇️

artículo científico publicado el 1 de agosto de 2011

Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma

artículo científico publicado en 2016

Histone Deacetylase Inhibitors Stimulate Histone H3 Lysine 4 Methylation in Part Via Transcriptional Repression of Histone H3 Lysine 4 Demethylases ⬇️

artículo científico publicado el 19 de octubre de 2010

Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry

artículo científico publicado en 2006

Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia

scientific article published on 16 April 2016

Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells

artículo científico publicado en 2003

Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality

artículo científico publicado en 2007

IGHV and Interphase Cytogenetics in a Patient With Chronic Lymphocytic Leukemia

artículo científico publicado en 2015

IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro

artículo científico publicado en 2008

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells

artículo científico publicado en 2014

IRF4(-/-)Vh11 mice: a novel mouse model of CLL.

artículo científico publicado en 2013

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity

artículo científico publicado en 2014

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

artículo científico publicado en 2013

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

artículo científico publicado en 2016

Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells

artículo científico publicado en 2015

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes ⬇️

artículo científico publicado el 25 de julio de 2013

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease

artículo científico publicado en 2014

Ibrutinib treatment improves T cell number and function in CLL patients

artículo científico publicado en 2017

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

artículo científico publicado en 2014

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

artículo científico publicado en 2014

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

artículo científico publicado en 2014

Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies

scientific article published on 16 April 2013

Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood

artículo científico publicado en 2003

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

artículo científico publicado en 2009

Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia

artículo científico publicado en 2015

Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies

artículo científico publicado en 2012

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

artículo científico publicado en 2017

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.

artículo científico publicado en 2014

Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies

scientific article published on September 2009

Improving the Treatment Outcome of Patients with Chronic Lymphocytic Leukemia Through Targeted Antibody Therapy ⬇️

artículo científico publicado el 1 de abril de 2013

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

scientific article published on 23 July 2015

In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia ⬇️

artículo científico publicado el 22 de noviembre de 2012

In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation

artículo científico publicado en 2013

Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.

artículo científico publicado en 2011

Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans

artículo científico publicado en 2014

Increasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis ⬇️

artículo científico publicado el 16 de agosto de 2013

Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia

artículo científico publicado en 2016

Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells

artículo científico publicado en 2016

Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia.

artículo científico publicado en 2005

Isolation and analysis of linker histones across cellular compartments

artículo científico publicado en 2013

Jumping translocations, a novel finding in chronic lymphocytic leukaemia

artículo científico publicado en 2015

KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis

artículo científico publicado en 2003

Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells

artículo científico publicado en 2016

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

artículo científico publicado en 2008

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway

artículo científico publicado en 2009

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia

artículo científico publicado en 2012

Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment

artículo científico publicado en 2008

Liquid chromatography mass spectrometry profiling of histones

artículo científico publicado en 2007

Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma

artículo científico publicado en 2007

Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing ⬇️

artículo científico publicado el 5 de septiembre de 2013

Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation1 ⬇️

artículo científico publicado el 15 de septiembre de 2003

MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions

artículo científico

Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia

artículo científico publicado en 2004

Mass Cytometry: A High-Throughput Platform to Visualize the Heterogeneity of Acute Myeloid Leukemia

artículo científico publicado en 2015

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab

artículo científico publicado en 2008

Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity

artículo científico publicado en 2007

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines

artículo científico publicado en 2007

Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia

artículo científico publicado en 2007

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.

artículo científico publicado en 2009

MicroRNA-29b mediates altered innate immune development in acute leukemia

artículo científico publicado en 2016

Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells

artículo científico publicado en 2010

Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies

artículo científico publicado en 2012

Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers

artículo científico publicado en 2002

Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes

artículo científico publicado en 2007

Monoclonal antibody therapy in lymphoid leukemias

artículo científico publicado en 2004

MuCor: mutation aggregation and correlation

artículo científico publicado en 2016

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies

artículo científico publicado en 2018

Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality

artículo científico publicado en 2016

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment

artículo científico publicado en 2016

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas

artículo científico publicado en 2010

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.

artículo científico publicado en 2017

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

artículo científico publicado en 2016

NF-κB functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cells

artículo científico publicado en 2014

NF-κB p50 (nfkb1) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia

artículo científico publicado en 2017

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome

NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines

artículo científico publicado en 2016

Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia

artículo científico publicado en 2006

New drugs for chronic lymphocytic leukemia

artículo científico publicado en 2006

Nitric Oxide Production by Myeloid Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function

artículo científico publicado en 2018

Non-Hodgkin's Lymphomas, version 3.2012

artículo científico publicado en 2012

Non-Hodgkin's lymphomas

artículo científico publicado en 2008

Non-Hodgkin's lymphomas

artículo científico publicado en 2011

Non-Hodgkin's lymphomas, version 1.2013.

artículo científico publicado en 2013

Non-Hodgkin's lymphomas, version 2.2014

artículo científico publicado en 2014

Non-Hodgkin's lymphomas, version 4.2014.

artículo científico publicado en 2014

Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3.

artículo científico publicado en 2007

Novel Therapies and Their Integration into Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia ⬇️

artículo científico publicado el 1 de enero de 2012

Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia

artículo científico publicado en 2007

Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia

artículo científico publicado en 2012

OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells

artículo científico publicado en 2014

OSU‐DY7, a novel D‐tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen‐activated protein kinase pathway ⬇️

artículo científico publicado el 7 de abril de 2011

Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia

artículo científico publicado en 2014

Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients

artículo científico publicado en 2014

PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.

artículo científico publicado en 2014

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

artículo científico publicado en 2013

Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.

artículo científico publicado en 2013

Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia

artículo científico publicado en 2010

Pentostatin in steroid-refractory acute graft-versus-host disease

artículo científico publicado en 2005

Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia

artículo científico publicado en 2007

Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance)

artículo científico publicado en 2019

Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia

artículo científico publicado en 2016

Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice ⬇️

artículo científico publicado el 7 de septiembre de 2012

Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2013

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

artículo científico publicado en 2002

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

artículo científico publicado en 2010

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia

scientific article published on 15 August 2018

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma

artículo científico publicado en 2010

Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias

artículo científico publicado en 2010

Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma

artículo científico publicado en 2015

Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia ⬇️

artículo científico publicado el 1 de noviembre de 2013

Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia

artículo científico publicado en 2008

Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia ⬇️

artículo científico publicado el 9 de septiembre de 2013

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia

artículo científico publicado en 2007

Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia

artículo científico publicado en 2005

Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity

artículo científico publicado en 2005

Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia

artículo científico publicado en 2012

Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein

artículo científico publicado en 2011

Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation

artículo científico publicado en 2010

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

artículo científico publicado en 2009

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia

artículo científico publicado en 2006

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

artículo científico publicado en 2009

Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia ⬇️

artículo científico publicado el 5 de noviembre de 2010

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

artículo científico publicado en 2010

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies

artículo científico publicado en 2014

PrEMeR-CG: inferring nucleotide level DNA methylation values from MethylCap-seq data

artículo científico publicado en 2014

Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial

artículo científico publicado en 2020

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

artículo científico publicado en 2016

Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia

artículo científico publicado en 2009

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

artículo científico publicado en 2002

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials

artículo científico publicado en 2018

Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia

artículo científico

Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy

artículo científico publicado en 2010

Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.

artículo científico publicado en 2006

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

artículo científico publicado en 2014

Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma

artículo científico publicado en 2009

Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry

artículo científico publicado en 2014

Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia

artículo científico publicado en 2012

Quantitative analyses of DAPK1 methylation in AML and MDS

artículo científico publicado en 2011

Quantitative profiling of histone post-translational modifications by stable isotope labeling

artículo científico publicado en 2007

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

artículo científico publicado en 2002

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

artículo científico publicado en 2015

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia

artículo científico publicado en 2016

Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia

artículo científico publicado en 2021

Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy

artículo científico publicado en 2010

Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective

artículo científico publicado en 2014

Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)

artículo científico publicado en 2015

Regulation of acute graft-versus-host disease by microRNA-155.

artículo científico publicado en 2012

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia

artículo científico publicado en 2008

Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.

artículo científico publicado en 2004

Reprogramming Nurse-like Cells with Interferon γ to Interrupt Chronic Lymphocytic Leukemia Cell Survival

artículo científico publicado en 2016

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

artículo científico publicado en 2014

Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells

artículo científico publicado en 2011

Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib

artículo científico publicado en 2015

RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans ⬇️

artículo científico publicado el 3 de abril de 2012

Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia

artículo científico publicado en 2007

Rituximab in B-cell chronic lymphocytic leukemia

artículo científico publicado en 2003

Rituximab in chronic lymphocytic leukemia

artículo científico publicado en 2010

Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia

artículo científico publicado en 2017

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

artículo científico publicado en 2015

Second malignancies in B-cell chronic lymphocytic leukaemia: possible association with human papilloma virus

artículo científico publicado en 2010

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

artículo científico publicado en 2005

Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation

artículo científico publicado en 2015

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia ⬇️

artículo científico publicado el 3 de octubre de 2012

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

artículo científico publicado en 2015

Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue

artículo científico publicado en 2013

Signalling to drug resistance in CLL.

scientific article published on March 2010

Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL ⬇️

artículo científico publicado el 22 de noviembre de 2010

Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia

artículo científico publicado en 2013

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

artículo científico publicado en 2018

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.

artículo científico publicado en 2008

Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia

artículo científico publicado en 2015

Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia

artículo científico publicado en 2010

Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium ⬇️

artículo científico publicado el 1 de diciembre de 2010

Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study ⬇️

artículo científico publicado el 1 de diciembre de 2010

Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance

artículo científico publicado en 2005

Synthetic MicroRNA Cassette Dosing: Pharmacokinetics, Tissue Distribution and Bioactivity ⬇️

artículo científico publicado el 23 de mayo de 2012

TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia

artículo científico publicado en 2015

TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells

artículo científico publicado en 2008

TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia

artículo científico publicado en 2005

Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia

artículo científico publicado en 2010

Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia

artículo científico publicado en 2013

Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells ⬇️

artículo científico publicado el 28 de mayo de 2013

Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia

artículo científico publicado en 2012

Targeting BTK through microRNA in chronic lymphocytic leukemia

artículo científico publicado en 2016

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

artículo científico publicado en 2013

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical

artículo científico publicado en 2007

Targeting Interleukin-2-Inducible T-cell Kinase (ITK) in T-Cell Related Diseases.

artículo científico publicado en 2014

Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator

artículo científico publicado en 2016

Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase using PROTAC-mediated Degradation

artículo científico publicado en 2018

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission

scholarly article published 10 July 2018

Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals

artículo científico publicado en 2012

Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia

artículo científico publicado en 2010

The B-cell receptor pathway: a critical component of healthy and malignant immune biology

artículo científico publicado en 2014

The B-cell receptor signaling pathway as a therapeutic target in CLL.

artículo científico publicado en 2012

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

artículo científico publicado en 2016

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

artículo científico publicado en 2010

The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells ⬇️

artículo científico publicado el 20 de marzo de 2013

The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma

artículo científico publicado en 2009

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia

artículo científico publicado en 2010

The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

artículo científico publicado en 2015

The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia

artículo científico publicado en 2015

The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia

artículo científico publicado en 2009

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

artículo científico publicado en 2002

The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo

artículo científico publicado en 2010

The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo

artículo científico publicado en 2009

The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia

scientific article published on 15 March 2017

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia ⬇️

artículo científico publicado el 4 de marzo de 2011

Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia

artículo científico publicado en 2016

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

artículo científico publicado en 2002

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

artículo científico publicado en 2015

Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.

artículo científico publicado en 2009

Translating PI3K-Delta Inhibitors to the Clinic in Chronic Lymphocytic Leukemia: The Story of CAL-101 (GS1101).

artículo científico publicado en 2012

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

artículo científico publicado en 2005

Treatment of relapsed chronic lymphocytic leukemia: old and new therapies

artículo científico publicado en 2006

Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia

scientific article published on 10 February 2019

Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia

artículo científico publicado en 2015

Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection

artículo científico publicado en 2008

Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant

artículo científico publicado en 2018

Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia

artículo científico publicado en 2006

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia

artículo científico publicado en 2014

Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia

artículo científico publicado en 2009

Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study

artículo científico publicado en 2012

Venetoclax Adds a New Arrow Targeting Relapsed CLL to the Quiver

artículo científico publicado en 2016

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

artículo científico publicado en 2017

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

artículo científico publicado en 2004

Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors

artículo científico publicado en 2004

Eficacia de la azacitidina en comparación con los regímenes de atención convencionales en el tratamiento de los síndromes mielodisplásicos de mayor riesgo: un estudio de fase III, aleatorizado, abierto

artículo científico publicado en 2009

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda